金黄色葡萄球菌
微生物学
万古霉素
甲氧西林
耐甲氧西林金黄色葡萄球菌
抗生素
微球菌科
抗菌剂
医学
生物
细菌
遗传学
作者
Andrew S. Pumerantz,Krishna Muppidi,Sunil A. Agnihotri,Carlos Guerra,Vishwanath Venketaraman,Jeffrey Wang,Guru V. Betageri
标识
DOI:10.1016/j.ijantimicag.2010.10.011
摘要
Meticillin-resistant Staphylococcus aureus (MRSA) can persist in alveolar macrophages and contribute to clinical failure of intravenous vancomycin to cure pneumonia. In this study, it was shown that vancomycin in standard solution is unable to kill intracellular MRSA within macrophages. The intracellular viability of MRSA inside macrophages treated with two different formulations of encapsulated liposomal vancomycin prepared using a hydration–dehydration method was then determined. In contrast to the observations with standard vancomycin, treatment with conventional non-pegylated liposomal vancomycin (lacking any surface modification) resulted in a sufficient concentration of antibiotic inside the intracellular compartment of the macrophages to exert a marked bactericidal effect against MRSA. On the other hand, treatment of infected macrophages with surface-pegylated liposomes resulted in no impact on MRSA survival, and this lack of an inhibitory effect may likely reflect delayed phagocytosis owing to the ‘stealth’ effect by pegylation. This study indicates the potential for a novel liposomal delivery system that may improve clinical vancomycin treatment outcomes by targeting intracellular MRSA infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI